China SXT Pharmaceuticals (SXTC) Fundamental Analysis: Revenue, Earnings & Valuation

8.19 / 10

Outperform

Fundamental analysis rates SXTC as Outperform with an 8.2/10 quality score. Strengths include high inventory turnover, strong interest coverage, and favorable revenue‑to‑market‑value metrics. A weakness is the elevated current‑liabilities‑to‑total‑liabilities ratio (~98%), indicating potential balance‑sheet pressure.

Analysis Checks(9/10)

Revenue-MV

Value-0.28

Score3/3

Weight32.63%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value-11.72

Score2/3

Weight0.45%

1M Return0.13%

Inventory turnover ratio

Value0.84

Score3/3

Weight-3.20%

1M Return-0.93%

Current liabilities / Total liabilities (%)

Value98.13

Score0/3

Weight-13.79%

1M Return-4.96%

PB-ROE

Value-0.25

Score2/3

Weight30.44%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value0.05

Score2/3

Weight-1.15%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value27.69

Score2/3

Weight-3.78%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value-11.72

Score2/3

Weight0.18%

1M Return0.05%

Cost of sales ratio (%)

Value83.75

Score3/3

Weight0.94%

1M Return0.26%

Asset-MV

Value-0.49

Score3/3

Weight57.29%

1M Return11.61%

Is SXTC fundamentally strong?

SXTC scores 8.19/10 on fundamentals and holds a Discounted valuation at present. Backed by its -35.71% ROE, -576.72% net margin, -0.20 P/E ratio, 0.09 P/B ratio, and -16.70% earnings growth, these metrics solidify its Outperform investment rating.